Publications by authors named "Bart Corsaro"

The urgency and importance of organizing a global effort to harmonize clinical assay validation specific to the vaccine industry was identified during the drafting of the 2020 White Paper in Bioanalysis due to the lack of clarity and regulatory guidance/guidelines in vaccine immunoassay validation. Indeed, the Workshop on Recent Issues in Bioanalysis (WRIB) issues the White Paper in Bioanalysis yearly, which is one of the high-profile articles of the Journal focused on detailed discussions and recommendations on vaccine assay validation. Since 2017, participation in the WRIB working groups by vaccine assay validation experts and regulators has rapidly increased due to its unique format where industry leaders and regulators can meet and exchange ideas on topics of interest to both groups.

View Article and Find Full Text PDF

The 14 edition of the Workshop on Recent Issues in Bioanalysis (14 WRIB) was held virtually on June 15-29, 2020 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations, and regulatory agencies worldwide. The 14 WRIB included three Main Workshops, seven Specialized Workshops that together spanned 11 days in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy and vaccine. Moreover, a comprehensive vaccine assays track; an enhanced cytometry track and updated Industry/Regulators consensus on BMV of biotherapeutics by LCMS were special features in 2020.

View Article and Find Full Text PDF
Article Synopsis
  • The 2019 Workshop on Recent Issues in Bioanalysis (WRIB) held in New Orleans attracted over 1000 professionals from various sectors, including pharmaceuticals and regulatory agencies, focusing on current bioanalysis challenges and innovations.
  • The event featured extensive discussions on topics like bioanalysis methods, biomarkers, and regulatory compliance, leading to the creation of a comprehensive White Paper to guide the bioanalytical community.
  • The White Paper is divided into three parts, with Part 3 specifically addressing topics such as biomarker assay validation, reagent management strategies, and gene therapy challenges, while earlier parts discuss other key regulatory recommendations and method development.
View Article and Find Full Text PDF

Group B streptococcus (GBS) is a leading cause of young infant mortality and morbidity globally, with vaccines being developed for over four decades but none licensed to date. A serocorrelate of protection against invasive disease in young infants is being considered to facilitate vaccine early licensure, followed by demonstration of efficacy assessed postlicensure. In this Review, we synthesise the available scientific evidence to define an immune correlate associated with GBS disease risk reduction on the basis of studies of natural infection.

View Article and Find Full Text PDF